←
OserLab138 posts
OserLab avatar

OserLab

@Oser_Lab

OserLab @DanaFarber @harvardmed Seeks To Identify New Targeted Therapies For Small Cell Lung Cancer. Tweets/Views are my own.

◷ Joined November 2019▧ 1 Photos and videos
Dana-Farber News avatar
⟳ OserLab retweeted
Dana-Farber News@DanaFarberNews·Oct 24

In extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy meaningfully extended survival. @DanaFarber's Jacob Sands, MD, presents in the #ESMO26 Presidential Symposium. Read more: bit.ly/4yz9ntL

Post attachment
AACR avatar
⟳ OserLab retweeted
AACR@AACR·Oct 23

Small Cell Lung Cancer: Basic Mechanisms to Translational Advances— Trudy G. Oliver, Matthew G. Oser, and Julien Sage will address this topic in a plenary at the AACR Conference on Lung Cancer (Jan 14-17; San Diego). brnw.ch/21x6D39 #AACRlung27 @Oser_Lab @SageJulien

Post attachment
Journal of Clinical Investigation avatar
⟳ OserLab retweeted
Journal of Clinical Investigation@jclinicalinvest·Oct 21

EED helps small cell lung cancer keep its neuroendocrine state by repressing lung adenocarcinoma genes: doi.org/10.1172/JCI199454 Matthew G. Oser @oser_lab & team @danafarber & @BrighamWomens report the polycomb scaffolding subunit EED as a key supporter of small-cell lung cancer neuroendocrine identity and EGFR-mutant lung adenocarcinoma-to-small-cell lung cancer transformation. Notably, inactivation of EED in mice impaired small cell lung cancer tumorigenesis. The figure: EED inactivation promotes a shift from SCLC toward LUAD histology in an RPR2 GEMM in vivo. @the_asci #LungCancer #SCLC

Post attachment
OserLab avatar
OserLab@Oser_Lab·Oct 15

Beyond ASCL1, this study provides a generalizable framework for using complementary CRISPR-based screening approaches to dissect the regulation and function of lineage TFs in their endogenous cellular context. Congratulations to Keita, Kevin, and everyone involved in this work!

OserLab avatar
OserLab@Oser_Lab·Oct 15

In this work, we combine genome-wide CRISPR knockout screening with base editor screening to identify regulators of ASCL1 protein abundance in SCLC and uncover a mechanism by which HUWE1 controls ASCL1 degradation through its C-terminal phospho-degron.

OserLab avatar
OserLab@Oser_Lab·Oct 15

Excited to share another new study from our lab, co-led by Keita Masuzawa and Kevin Dong: “A HUWE1 Regulatory Helix Gates ASCL1 Degradation Through Its C-Terminal Phospho-Degron in Small Cell Lung Cancer.” genesdev.cshlp.org/content/e…

OserLab avatar
OserLab@Oser_Lab·Oct 15

This study was led by our fabulous postdoctoral fellow Yixiang Li, who drove the mouse modeling, wet-lab experiments, and bioinformatic analyses-a true tour de force! Yixiang is a K99 awardee and is currently on the faculty job market. He is an exceptionally talented!

OserLab avatar
OserLab@Oser_Lab·Oct 15

We find that EED helps maintain the NE identity of SCLC by repressing LUAD-associated oncogenic signaling programs. Our findings establish EED as an important regulator of SCLC NE identity and suggest EED inhibition as a strategy to prevent or alter SCLC transformation.

Bravo-Cordero Lab avatar
⟳ OserLab retweeted
Bravo-Cordero Lab@BravoCorderoLab·Aug 3

🚨We're growing! Our lab at @TischCancer is #recruiting postdocs for 3 fully funded NIH projects. If you want to explore the biology of tumor dormancy, join us!!! Projects focus on:🧠Cancer neuroscience, ECM-driven dormancy, HER2 biology. 📩 email for more info or send your CV👇

Post attachment
OserLab avatar
OserLab@Oser_Lab·Jul 19

Dear Colleagues, In two weeks, I’ll ride the Pan-Mass Challenge (162 miles) for the second year in honor of my parents and everyone affected by cancer.100% of every donation supports cancer research at DFCI. Please consider donating. Thank you in advance! profile.pmc.org/pmc/MO0250

OserLab avatar
OserLab@Oser_Lab·Apr 13

Excited to share our latest preprint, a wonderful collaboration w/ Matt Freedman and Sylvan Baca’s labs. Leveraging cfChIP-seq from patient plasma + functional mouse modeling, we uncover how TF subtype shapes response and resistance to tarlatamab in SCLC. biorxiv.org/content/10.64898…

Our latest collaboration with #MattFreedman and @Oser_Lab on resistance to tarlatamab: biorxiv.org/content/10.64898…. An exciting framework for studying cancer resistance: observations from patients using epigenomic #LiquidBiopsy -> functional validation in mouse models.

Post attachment